Philippe Vago

Philippe Vago

Auto-generated profile, based on publicly available information

Philippe Vago

CHU Clermont-Ferrand, Cytogénétique Médicale, Clermont-Ferrand, France

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2015 in Prenatal Diagnosis
Verified
Journal Article
Closed access
PDF file
FGFrancesca Romana Grati
Francesca Romana Grati
DGDenise Molina Gomes
Denise Molina Gomes
JFJose Carlos Pinto B. Ferreira
Jose Carlos Pinto B. Ferreira
CDCeline Dupont
Celine Dupont
VAViola Alesi
Viola Alesi
FVFrançois Vialard
François Vialard

16 January 2007 in British Journal of Cancer
Verified
Journal Article
Open access
ATA Tchirkov
A Tchirkov
TKT Khalil
T Khalil
ECEmmanuel Chautard
Emmanuel Chautard
KMK Mokhtari
K Mokhtari
LVL Véronèse
L Véronèse
PVP Verrelle
P Verrelle
Interleukin-6 (IL-6) is known to promote tumour growth and survival. We evaluated IL-6 gene amplification in tumours from 53 glioma patients using fluorescence in situ hybridisation. Amplification events were detected only in glioblastomas (15 out of 36 cases), the most malignant tumours, and were significantly associated with decreased patient survival.

1 August 2005 in Prenatal Diagnosis
Verified
Journal Article
Closed access
PDF file
CGCarole Goumy
Carole Goumy
ABA. M. Beaufrère
A. M. Beaufrère
CFC. Francannet
C. Francannet
ATA. Tchirkov
A. Tchirkov
HDH. Laurichesse Delmas
H. Laurichesse Delmas
PVP. Vago
P. Vago

4 October 2018 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
LKLaïla Allach El Khattabi
Laïla Allach El Khattabi
SHSolveig Heide
Solveig Heide
JCJean-Hubert Caberg
Jean-Hubert Caberg
JAJoris Andrieux
Joris Andrieux
MFMartine Doco Fenzy
Martine Doco Fenzy
EPEva Pipiras
Eva Pipiras
Background: The clinical significance of 16p13.11 duplications remains controversial while frequently detected in patients with developmental delay (DD), intellectual deficiency (ID) or autism spectrum disorder (ASD). Previously reported patients were not or poorly characterised. The absence of consensual recommendations leads to interpretation discrepancy and makes genetic counselling challenging. This study aims to decipher the genotype–phenotype correlations to improve genetic counselling and patients’ medical care. Methods: We retrospectively analysed data from 16 013 patients referred to 12 genetic centers for DD, ID or ASD, and who had a chromosomal microarray analysis. The referring geneticists of patients for whom a 16p13.11 duplication was detected were asked to complete a questionnaire for detailed clinical and genetic data for the patients and their parents. Results: Clinical features are mainly speech delay and learning disabilities followed by ASD. A significant risk of cardiovascular disease was noted. About 90% of the patients inherited the duplication from a parent. At least one out of four parents carrying the duplication displayed a similar phenotype to the propositus. Genotype–phenotype correlations show no impact of the size of the duplicated segment on the severity of the phenotype. However, NDE1 and miR-484 seem to have an essential role in the neurocognitive phenotype. Conclusion: Our study shows that 16p13.11 microduplications are likely pathogenic when detected in the context of DD/ID/ASD and supports an essential role of NDE1 and miR-484 in the neurocognitive phenotype. Moreover, it suggests the need for cardiac evaluation and follow-up and a large study to evaluate the aortic disease risk.

1 May 2002 in Neuroscience
Verified
Journal Article
Closed access
JWJ Wang
J Wang
MDM Dib
M Dib
MLM Lenoir
M Lenoir
PVP Vago
P Vago
MEM Eybalin
M Eybalin
JPJean-Luc Puel
Jean-Luc Puel

23 October 2017 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
ATAnne-Claude Tabet
Anne-Claude Tabet
TRThomas Rolland
Thomas Rolland
MDMarie Ducloy
Marie Ducloy
JLJonathan Levy
Jonathan Levy
JBJulien Buratti
Julien Buratti
TBThomas Bourgeron
Thomas Bourgeron
Phelan-McDermid syndrome (PMS) is characterized by a variety of clinical symptoms with heterogeneous degrees of severity, including intellectual disability (ID), absent or delayed speech, and autism spectrum disorders (ASD). It results from a deletion of the distal part of chromosome 22q13 that in most cases includes the SHANK3 gene. SHANK3 is considered a major gene for PMS, but the factors that modulate the severity of the syndrome remain largely unknown. In this study, we investigated 85 patients with different 22q13 rearrangements (78 deletions and 7 duplications). We first explored the clinical features associated with PMS, and provide evidence for frequent corpus callosum abnormalities in 28% of 35 patients with brain imaging data. We then mapped several candidate genomic regions at the 22q13 region associated with high risk of clinical features, and suggest a second locus at 22q13 associated with absence of speech. Finally, in some cases, we identified additional clinically relevant copy-number variants (CNVs) at loci associated with ASD, such as 16p11.2 and 15q11q13, which could modulate the severity of the syndrome. We also report an inherited SHANK3 deletion transmitted to five affected daughters by a mother without ID nor ASD, suggesting that some individuals could compensate for such mutations. In summary, we shed light on the genotype-phenotype relationship of patients with PMS, a step towards the identification of compensatory mechanisms for a better prognosis and possibly treatments of patients with neurodevelopmental disorders.